Early trial shows first-ever vaccine for brain tumours is safe, effective

For the first time, physicians and cancer researchers have carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumours and found the vaccine to be safe and that it triggered the desired immune response in the tumor tissue.

Mutations in the tumour genome often lead to protein changes that are typical of cancer. Tumor vaccines can help the body fight cancer, as it can alert the patient’s immune system to these mutated proteins.

In their report published in the journal Nature and featured in medicalexpresss.com, the study director, Michael Platten, Medical Director of the Department of Neurology of University Medicine Mannheimhttps://www.uni-heidelberg.de/en and Head of Division at the German Cancer Research Center (DKFZ) says the idea was to support patients’ immune systems and to use a vaccine as a targeted way of alerting it to the tumor-specific neo-epitope.

“The IDH1 mutation is a particularly suitable candidate here, as it is highly specific to the gliomas and does not occur in healthy tissue. Moreover, the IDH1 mutation is responsible for the development of these gliomas: “That means that a vaccine against the mutated protein allows us to tackle the problem at the root,” Platten said.

Diffuse gliomas are usually incurable brain tumors that spread throughout the brain and are difficult to remove completely by surgery. Chemotherapy and radiotherapy often have only a limited effect. In many cases, diffuse gliomas share a common feature: In more than 70% of patients, the tumor cells have the same gene mutation. An identical error in the DNA causes a single, specific protein building block to be exchanged in the IDH1 (Isocitrate dehydrogenase 1) enzyme. This creates a novel protein structure, known as a neo-epitope, which can be recognized as foreign by the patient’s immune system.

Platten’s team from Heidelberg and Mannheim in Germany generated an artificial version of the segment of the IDH1 protein with the characteristic mutation several years ago. This mutation-specific peptide vaccine was able to halt the growth of IDH1-mutated cancer cells in mice. In 2019, Platten was awarded the German Cancer Prize for this discovery.

Encouraged by these results, Platten and a team of physicians decided to test the mutation-specific vaccine for the first time in a phase I study in patients newly diagnosed with a IDH1-mutated glioma (WHO grades III and IV astrocytomas). A total of 33 patients at several different centers in Germany were enrolled in the study. In addition to the standard treatment, they received the peptide vaccine produced by Michael Schmitt, head of cellular immunotherapy, Department of Hematology, Oncology and Rheumatology at Heidelberg University Hospital, and Stefan Stevanovic, professor of molecular immunology at the Department of Immunology, University of Tübingen. The immune response was evaluated in 30 patients.

The physicians did not observe any serious side effects in any of the patients who were vaccinated. In 93% of the patients, the immune system showed a specific response to the vaccine peptide and did so regardless of the patient’s genetic background, which determines the immune system’s important presentation molecules, the HLA proteins.

In a large proportion of the vaccinated patients, the physicians observed pseudoprogression, swelling of the tumor caused by a host of invading immune cells. These patients had a particularly large number of T helper cells in their blood with immune receptors that responded specifically to the vaccine peptide, as single cell sequencing revealed. “We were also able to demonstrate that the activated mutation-specific immune cells had invaded the brain tumor tissue,” reported Theresa Bunse from DKFZ, who coordinated the immunological analyses for these studies.

The three-year survival rate after treatment was 84% in the fully vaccinated patients, and in 63% of patients tumor growth had not progressed within this period. Among the patients whose immune system showed a specific response to the vaccines, a total of 82% had no tumor progression within the three-year period.

“We cannot draw any further conclusions about the vaccine efficacy from this early study without a control group,” remarked Michael Platten.

“The safety and immunogenicity of the vaccine were so convincing that we continued to pursue the vaccine concept in a further phase I study.”

In this follow-on study, the researchers are combining the IDH1 vaccine with checkpoint inhibitor immunotherapy.

Source: www.medicalexpress.com

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here